Small development-stage biotech with ample cash and a partnership with Sanofi . Heart disease focus with initial compound entering Phase 3 trials. No immediate catalysts, but looks like a decent technical setup. Momentum leader that has quadrupled over the past year, currently in a meaningful pullback.

Ideally would like to see it test the Feb lows and rising trend support around 47.50. But if it's strong out of the gate tomorrow, I might just buy in.
Mar 19
Trade active: Did buy in, as the stock is really strong out of the gate.
Apr 10
Comment: Been a long time. But for those that are still in or interested, I think it once again sets up well.
Home Stock Screener Forex Screener Crypto Screener Economic Calendar Shows How It Works Chart Features Pricing House Rules Moderators Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Help Center Refer a friend Feature Request Blog & News FAQ Wiki Twitter
Profile Profile Settings Account and Billing Refer a friend My Support Tickets Help Center Ideas Published Followers Following Private Messages Chat Sign Out